Newsletters
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
CDC: Funding opportunities (1 each) in US, Africa, and Asia
Dear All: CDC have recently posted this eclectic mixture of funding opportunities that circle the globe! Funding opportunity: CDC-RFA-CK-26-0107 Title: ...
Read More >
PACCARB returns! 16 June 2026 virtual meeting
Dear All: Without much fanfare, we have an announcement that PACCARB (the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) ...
Read More >
EUR 20m funding for next-gen diagnostics for LRTIs (Novo Nordisk Foundation)
Dear All: I have just learned of a recently opened grant program from NNF (Novo Nordisk Foundation) that seeks to ...
Read More >
Economic modeling of the value of rapid diagnostics
Dear All (and again with thanks to Arjun Srinivasan for co-authoring this pair of newsletters): In parallel with the newsletter ...
Read More >
Limits on measuring the impact of rapid antimicrobial susceptibility testing (AST)
Dear All (and with thanks to Arjun Srinivasan for co-authoring this wonkish newsletter — prepare yourself! Know also that we’ve ...
Read More >
BARDA seeks info on Phase 2+ antifungals for Candida and Aspergillus
Dear All: As discussed in prior newsletters, BARDA is constantly working to ensure it has adequate medical countermeasures (MCMs) for ...
Read More >
CARB-X seeks two Assistant Directors of External Affairs
Dear All: Starting to get caught up after some time on vacation! For today, we have announcement by CARB-X of ...
Read More >
DTR Gram-negative infections: Are new antibiotics making a difference?
Dear All (and with thanks to Aaron Dane for co-authoring this newsletter AND inhale, exhale … this is going to be ...
Read More >
AMR Science-Policy Symposia (ESCMID 2026): Smart policies for lean times
Dear All: ESCMID Global once again held an afternoon of sessions focused on the intersection of AMR-related science and policy. ...
Read More >
Wellcome Leap: $50m for gut-sparing approaches to antibiotic delivery
Dear All: I’ve just learned of a funding call from Wellcome Leap entitled “Focused antibiotics.” The thesis of the call ...
Read More >
Anti-Gram-negative beta-lactams in jeopardy: The rise of PBP3 mutations
Dear All (and with thanks to Robert Bonomo and Patricia Bradford for guiding me on this newsletter; anything that’s correct ...
Read More >
AMR Surveillance Data Challenge – Vivli 2026 Call for Projects!
Dear All, I’ve written before about the Vivli data challenge (2024 edition, 2025 edition) and am pleased to be able ...
Read More >
GO-Dx: Global One Health Diagnostics Access Compact
Dear All, Building on the concepts of the January 2016 Industry-led Davos Declaration on action on AMR (website;.pdf declaration; yes, ...
Read More >
The language of AMR: The power of metaphor
Dear All, Acronyms and jargon fill our daily scientific lives but can be impenetrable to newcomers. A great example is ...
Read More >
Great AMR-focused podcast series on BBC Discovery!
Dear All, The BBC’s Roland Pease has put together a 3-part podcast series on AMR! Each episode is about 30 ...
Read More >
Antimicrobial Effectiveness: The strategic economic value of antibiotics
Dear All (and with thanks to Lucy Naga for being the lead author on this economic-focused newsletter), Antimicrobials are the ...
Read More >
WHO: New TPPs for antibacterial agents
Dear All, You may recall that in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A ...
Read More >
EMA: “Regulatory sandboxes” to explore approval pathways
Dear All, No, EMA has not decided to set up shop on the beach! Rather, the point of this newsletter is ...
Read More >
CARB-X seeks new Chief of R&D (fully remote, worldwide)
Dear All, A very senior and globally significant leadership opportunity has appeared: CARB-X is seeking to recruit a new Chief of Research ...
Read More >
FDA: One pivotal trial (+ confirmatory evidence) is default expectation for approval
Dear All (a wonkish guide to something you may have thought was obvious AND with thanks to Aaron Dane for ...
Read More >